Ultime notizie per Quantum Computing (NASDAQ:QUBT) Azioni

Quantum Computing

Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.

Advanced,Quantum,Computing,Data,On,Computer,Screen.,Close,Up,On

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

News

Markets

Tech

$BTC

GOOG

GOOGL

MSFT

QUBT

RGTI

Michael Saylor, uno dei massimi sostenitori di Bitcoin (CRYPTO: BTC), non sembra troppo preoccupato dalla potenziale minaccia che il quantum computing potrebbe rappresentare per la sicurezza della rete.

Il Quantum Computing è una minaccia per Bitcoin? Ecco la verità

Los,Angeles,-,Apr,15:,Chamath,Palihapitiya,At,The,9th

Giovedì, il venture capitalist Chamath Palihapitiya ha definito l’oro come l&#39;”unico investimento sicuro”, a seguito di notizie che suggeriscono come i computer quantistici potrebbero essere in grado di decifrare la crittografia di Bitcoin (CRYPTO: BTC)

Bitcoin è in pericolo? La minaccia si chiama quantum computing

Jensen,Huang,Nvidia's,Founder,,President,And,Ceo,Gestures,During,A

Market Summary

ETFs

AMZN

IONQ

NVDA

QBTS

QTUM

Il calcolo quantistico è un settore in rapida crescita. Quali sono le aziende che potrebbero cambiare il futuro della tecnologia?

Calcolo quantistico: le migliori aziende su cui puntare per il futuro

Barclays analyst Benjamin Budish maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underweight and raises the price target from $19 to $20.

Price Target

Analyst Ratings

Barclays Maintains Underweight on Franklin Resources, Raises Price Target to $20

MCRP

Micropolis And Hader Security And Communication Systems Sign MOU To Integrate AI-Driven Mobility And Secure Communications Across Public And Private Sectors

CYCC

Cyclacel Pharmaceuticals Says Not Aware Of Any Material Developments Or Changes To Operating Or Financial Condition That Precipitated Jul. 15 Volume And Price Movements

Mizuho analyst Anthony Petrone maintains Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) with a Outperform and lowers the price target from $105 to $90.

Mizuho Maintains Outperform on Cooper Companies, Lowers Price Target to $90

14 analysts have shared their evaluations of Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $182.64, a high estimate of $205.00, and a low estimate of $159.00. This current average has increased by 8.81% from the previous average price target of $167.85. 
<img src="https://www.benzinga.com/files/images/story/2025/1752670985_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A clear picture of Marathon Petroleum's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Justin Jenkins</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$180.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$189.00</td>
<td>$159.00</td>
</tr>
<tr>
<td>Manav Gupta</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$203.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Justin Jenkins</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$188.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>In-Line</td>
<td>$170.00</td>
<td>-</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$184.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Theresa Chen</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$159.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Marathon Petroleum. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Marathon Petroleum compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Marathon Petroleum's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Marathon Petroleum's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MPC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Marathon Petroleum analyst ratings.</a>
<h2>All You Need to Know About Marathon Petroleum</h2>
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 3.0 million barrels per day. Its Dickinson, North Dakota, facility produces 184 million gallons a year of renewable diesel. Its Martinez, California, facility has the ability to produce 730 million gallons a year of renewable diesel. The firm also owns and operates midstream assets primarily through its listed master limited partnership, MPLX.
<h3>Financial Milestones: Marathon Petroleum's Journey</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Decline in Revenue: Over the 3M period, Marathon Petroleum faced challenges, resulting in a decline of approximately -3.64% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.23%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Marathon Petroleum's ROE excels beyond industry benchmarks, reaching -0.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Marathon Petroleum's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.09% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.96.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 14 Analysts Discuss Marathon Petroleum Stock

FRGT

Freight Technologies Deploys Ai-Powered Voice Agents As Part Of Fetch.ai Collaboration

Barclays analyst Benjamin Budish maintains AllianceBernstein Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) with a Equal-Weight and raises the price target from $37 to $40.

Barclays Maintains Equal-Weight on AllianceBernstein Holding, Raises Price Target to $40

ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ResMed and provided 12-month price targets. The average target is $270.14, accompanied by a high estimate of $290.00 and a low estimate of $248.00. This current average has increased by 0.48% from the previous average price target of $268.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1752670933_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of ResMed among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Craig Wong-Pan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$255.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Laura Sutcliffe</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$285.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>David Low</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$290.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$248.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$274.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$269.00</td>
<td>$280.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ResMed. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ResMed compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for ResMed's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of ResMed's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RMD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ResMed analyst ratings.</a>
<h2>Get to Know ResMed Better</h2>
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
<h3>ResMed's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: ResMed's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 7.92%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: ResMed's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 28.26%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ResMed's ROE excels beyond industry benchmarks, reaching 6.76%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ResMed's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: ResMed's debt-to-equity ratio is below the industry average at 0.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For ResMed's Future

Mizuho analyst Anthony Petrone maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Neutral and lowers the price target from $150 to $130.

Mizuho Maintains Neutral on Teleflex, Lowers Price Target to $130

Mizuho analyst Anthony Petrone maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Neutral and raises the price target from $17 to $18.

STAA

Mizuho Maintains Neutral on Staar Surgical, Raises Price Target to $18

UBS Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) short percent of float has risen 4.55% since its last report. The company recently reported that it has 7.36 million shares sold short, which is 0.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>UBS Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752670852_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UBS Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing UBS Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, UBS Gr's peer group average for short interest as a percentage of float is 2.19%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About UBS Gr?

Bright Horizons Family's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) short percent of float has fallen 3.05% since its last report. The company recently reported that it has 907 thousand shares sold short, which is 1.59% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.54 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Bright Horizons Family Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752670842_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bright Horizons Family has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Bright Horizons Family's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bright Horizons Family's peer group average for short interest as a percentage of float is 4.45%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

BFAM

Is Bright Horizons Family Gaining or Losing Market Support?

Walgreens Boots Alliance's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NYSE">WBA</a>) short percent of float has risen 26.69% since its last report. The company recently reported that it has 21.25 million shares sold short, which is 3.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Walgreens Boots Alliance Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752670837_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Walgreens Boots Alliance has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Walgreens Boots Alliance's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Walgreens Boots Alliance's peer group average for short interest as a percentage of float is 2.49%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Do Investors Really Feel About Walgreens Boots Alliance?

Barclays analyst Ross Sandler maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Overweight and raises the price target from $5600 to $5700.

BKNG

Barclays Maintains Overweight on Booking Holdings, Raises Price Target to $5700

Century Aluminum Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) ("Century") announced today a proposed private offering of $400 million aggregate principal amount of senior secured notes due July 2032 (the "Secured Notes") subject to market and other conditions (the "Secured Notes Offering"). Century intends to use the net proceeds from the Secured Notes Offering to refinance Century's 7.50% Senior Secured Notes due 2028 (the "2028 Notes"), to repay borrowings under Century's credit facilities and to pay fees and expenses relating to these transactions.
The interest rate and other terms of the Secured Notes will be determined at the pricing of the Secured Notes Offering.

Offerings

CENX

Century Aluminum Company Announces A Proposed Private Offering Of $400M Aggregate Principal Amount Of Senior Secured Notes Due July 2032

Barclays analyst Trevor Young maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Underweight and raises the price target from $103 to $104.

ABNB

Barclays Maintains Underweight on Airbnb, Raises Price Target to $104

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
&nbsp;
Resignation of Chief Executive Officer and Chief Financial Officer
&nbsp;
In July 2025, the Board of Directors (the "Board") of Primega Group Holdings Limited (the "Company") received and accepted the resignation of Mr. Man Siu Ming ("Mr. Man") from his position as Chief Executive Officer and the resignation of Mr. Lau Mei Suen ("Mr. Lau") from his position as Chief Financial Officer, both effective immediately. Each of Mr. Man and Mr. Lau resigned for personal reasons and not due to any disagreement with the Company or the Board on any matter relating to the Company's operations, policies, or practices. Mr. Man will continue to serve the Company as General Manager.
&nbsp;
Appointment of Chief Executive Officer and Chief Financial Officer
&nbsp;
Effective July 16, 2025, the Board appointed Mr. Tan Yu ("Mr. Tan") as Chief Executive Officer and Ms. Liu Wei ("Ms. Liu") as Chief Financial Officer of the Company.
&nbsp;
Mr. Tan holds a Bachelor's degree from Jilin University. He has served in multiple C-suite roles across a range of companies, where he was responsible for corporate operations, strategic planning, and organizational oversight. His experience spans several industries and includes both managing day-to-day business activities and directing long-term initiatives. Mr. Tan will contribute to the Company's overall management and support the execution of its strategic objectives.
&nbsp;
Ms. Liu holds a Bachelor's degree in Finance from Heilongjiang University of Commerce. She has experience in financial management and compliance, including a prior role as finance manager with responsibilities encompassing budgeting, internal controls, and the implementation of financial systems. Ms. Liu will contribute to the Company's financial operations and ongoing compliance initiatives.

Management

ZDAI

Primega Group Holdings Announces Man Siu Ming Resigns As Chief Executive Officer; Lau Mei Suen Steps Down As Chief Financial Officer; Board Appoints Tan Yu As CEO, Liu Wei As CFO

Morgan Stanley analyst Connor Lynagh maintains Delek US Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DK#NYSE">DK</a>) with a Underweight and raises the price target from $15 to $19.

Morgan Stanley Maintains Underweight on Delek US Hldgs, Raises Price Target to $19

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/16025108/Tian-Tu-0716-900x600-1.png" alt="" class="wp-image-15896" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/16025108/Tian-Tu-0716-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/16025108/Tian-Tu-0716-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/16025108/Tian-Tu-0716-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The private equity investor appears to be setting its sights on high-tech companies as it prepares to raise funds by issuing bonds
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Tain Tu Capital is looking to raise up to 300 million yuan by issuing bonds that it's calling "Sci-Tech Innovation Notes"</li>
<li>The move comes as the private equity investor's growth stagnates amid sluggishness for its core focus on consumer-related Chinese companies</li>
</ul>
Private equity and venture capital veteran Tian Tu Capital Co. Ltd. (1973.HK) is preparing to broaden its horizons as its traditional focus on China's once-vibrant consumer sector rapidly loses economic steam.
Last Thursday, the company&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0710/2025071000892.pdf">said</a>&nbsp;it's looking to raise up to 300 million yuan ($42 million) by issuing bonds that it's calling "Sci-Tech Innovation Notes" in one or more private offerings for institutional investors. Tian Tu plans to use at least 70% of the proceeds to finance investment funds or for its own equity investments, and spend the rest on other purposes, including replenishment of its working capital.
The company didn't specify what sectors it will chase with the new capital, but the "sci-tech" name heavily suggests it has set its sights on high-tech enterprises. Such a pivot wouldn't be completely out of the blue for this company better known for its consumer focus, with an investment portfolio including the likes of bubble tea chain Nayuki and infant formula maker Feihe. In its latest annual report, the company said it wants to broaden its investment scope to emerging areas like biotechnology and robotics as it tries to "uncover innovative investment themes and strategies."
Tian Tu, a seasoned private equity and venture capital firm that's been around more than two decades, previously thrived on rising Chinese consumerism, which fueled its growth for years as a booming economy created an increasingly wealthy middle class.
But that was then, and this is now. China's economic growth has cooled considerably in the last few years, with no easy fix in sight. The country's property sector, which accounts for a large part of its GDP, is ailing after speculators pushed prices to meteoric heights and a relentless debt-fueled expansion created massive oversupply. China is also facing a long list of challenges externally, including trade tensions with Donald Trump, a major headache for its export-oriented economy.
Those macroeconomic troubles are trickling down to average Joes in the form of slow income growth and even layoffs. That means greater difficulty in boosting sales for consumer businesses, which in turn makes life harder for Tian Tu in a number of ways.
Among other things, it becomes more difficult for the company to attract investors to its funds as its primary retail-related target companies become less attractive. Perhaps reflecting that, Tian Tu's assets under management shrank about 16% to 20.5 billion yuan at the end of last year from 12 months earlier. The amount of new capital raised by Tian Tu's funds last year also dropped by nearly two-thirds to 401 million yuan.
As the company struggled to attract investors, its revenue fell about 5% to 44.6 million yuan last year from 2023. It has two main revenue sources: fund management fees and so-called carried interest, or a cut of realized gains from investment funds it manages. Tian Tu didn't book any income from the latter category last year, which means its revenue growth came solely on its ability to grow its fund management portfolio.
Tian Tu is also facing the additional challenge of falling valuations in its portfolio companies. To account for that last year, it continued to book substantial investment losses amounting to 705 million yuan on a net basis, dwarfing its revenue for the period.
In the current climate, Tian Tu may also be having difficulty finding promising new retail-related investment targets, and face similar problems exiting its existing investments through IPOs or sales. So, its attempt to broaden its investment scope makes sense, although it might face greater competition in high-tech areas that are typically favorites among private equity and venture capital investors.
Contrary to Tian Tu's struggles, business is booming for major investment banks like China International&nbsp;Capital Corp. Ltd.&nbsp;(3908.HK; 601995.SH) on the back of a resurgent IPO market in Hong Kong. On Tuesday, CICC said it expects to report year-on-year profit growth of as much as 78% for the first half of this year. This indicates that investors may feel more comfortable with putting their money in relatively established companies that go public than betting on startups that are the focus of private equity firms like Tian Tu, especially in tepid sectors like retail.
Among Tian Tu's apparent new interest areas, biotechnology isn't entirely new to the company. In 2022 alone, it invested in two early-stage companies in that sector. And robotics are all the rage in China at the moment, which could yield other promising opportunities.
<h4 class="wp-block-heading">Debt financing</h4>
In terms of financing, bond issuance has some practical benefits as well. For starters, bond financing could be cheaper than soliciting contributions from investors for purpose-specific funds, since borrowing costs are currently pretty low in China as the country's central bank keeps interest rates down to stimulate economic growth. And at the end of the day, debt is generally cheaper than equity, as investors in the latter demand higher returns for the higher risks they take. So, it's not uncommon for private equity firms to use borrowing to juice up returns on their investments.
Also, by securing funds by issuing bonds, Tian Tu can deploy capital quickly when it finds a good investment target without waiting for investors to send their committed capital. Moreover, the company can raise funds based purely on its own creditworthiness and use the money freely, unlike equity capital that typically goes to a specific investment.
The issuance of Sci-Tech Innovation Notes will reduce Tian Tu's "financing costs, diversity its funding channels, expand its business scale, and enhance its profitability and risk resilience," the company said.
Tian Tu shares are down more than 30% from their IPO price in 2023 and trade at a price-to-book (P/B) ratio of just 0.3, compared to 0.7 for CICC.&nbsp;China Renaissance&nbsp;(1911.HK), a similar boutique fund manager that both invests and offers investment banking services, trades in between the pair with a P/B ratio of 0.5, showing that Tian Tu needs to up its game to return to investor favor.
It thinks the answer might lie in high-tech investments. Now, Tian Tu needs to successfully execute that pivot and return to growth – something that may be easier said than done as it faces a complex challenge of stiff competition for quality investments in a slowing Chinese economy.

Asia

Global

Opinion

Private Equity Investor Tian Tu Capital Eyes New Frontiers As China's Consumer Sector Stalls

Morgan Stanley analyst Connor Lynagh maintains HF Sinclair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>) with a Overweight and raises the price target from $44 to $50.

DINO

Morgan Stanley Maintains Overweight on HF Sinclair, Raises Price Target to $50

Press Releases

Quantum Computing Inc. Announces Private Placement of Common Stock for Proceeds of $200 Million

Fintech

Mutual Funds

Tradr Launches Leveraged ETFs on Quantum Computing Inc. (QUBT) and Rigetti Computing (RGTI)

Quantum Computing Inc. Announces Closing of Private Placement of Common Stock for Proceeds of $200 Million

Legal

QCI ALERT: Bragar Eagel & Squire, P.C. is Investigating Quantum Computing, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

QUANTUM COMPUTING INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Quantum Computing Inc. - QUBT

Johnson Fistel, PLLP Investigates Quantum Computing, AppLovin, Skyworks Solutions, and Maravai LifeSciences

Quantum Computing Emerging as a Transformative Technology with Potential Applications in Drone Technology

Tradr Launches First-to-Market Leveraged ETFs on CoreWeave, AST SpaceMobile, Constellation Energy, GE Vernova and NuScale Power

QUANTUM COMPUTING INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Quantum Computing Inc. - QUBT

Comments

Quantum Computing

Notizie

Ultime notizie per Quantum Computing (NASDAQ:QUBT) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO